: Ongoing efforts aim to revise PDA TR 82 to align with the latest scientific understanding and analytical capabilities
The PDA Technical Report 82 is aligned with regulatory requirements and guidelines from various regulatory agencies, including:
The science of LER is not static. Since the report's publication in 2019, the industry has gained significant experience, revealing new challenges and areas for improvement. As of 2025, a major revision of TR 82 is underway, led by a dedicated PDA task force.
According to the official product description, PDA TR 82 aims to: pda technical report 82
The PDA Technical Report 82 has been widely adopted by pharmaceutical and biotechnology companies, regulatory agencies, and industry professionals. Implementation of the guideline can bring several benefits, including:
For decades, the Limulus amebocyte lysate (LAL) test has served as the gold standard for detecting bacterial endotoxins in parenteral drugs, providing a critical safety barrier between patients and potentially pyrogenic contaminants. But what happens when that test stops working? , represents the pharmaceutical industry’s first comprehensive response to Low Endotoxin Recovery (LER)—a phenomenon that undermines traditional endotoxin detection in modern biologic drugs.
For more information, the full text of PDA Technical Report 82 is available through the PDA Bookstore and Technical Report Portal. PDA members receive 30 days of free access to new technical reports upon publication. Professionals interested in contributing to the ongoing revision can apply through the PDA peer reviewer volunteer opportunity portal. : Ongoing efforts aim to revise PDA TR
TR 82 serves as a defense for companies utilizing this non-standard method. During an inspection, a regulator may question why a water system is sanitized at low velocity.
By the mid-2010s, the FDA began formally requesting LER-type hold-time studies as a requirement for Biologics License Applications (BLAs), particularly for products with formulations prone to endotoxin masking. In BLA review letters, the FDA has explicitly required sponsors to "evaluate the effect of hold time on endotoxin detection by spiking a known amount of standard endotoxin into undiluted DP and test for recoverable endotoxin over time".
In keeping with PDA’s commitment to rigorous scientific consensus, the draft report underwent an exceptionally thorough review involving . This multi-stage review process, documented at every level of comment resolution, ensures that TR 82 represents not merely one company’s perspective but the collective wisdom of the entire parenteral drug community. According to the official product description, PDA TR
One particularly active debate concerns the . PDA TR 82 specifies the use of Control Standard Endotoxin (CSE) or Reference Standard Endotoxin (RSE) as preferred standards. Yet some experts argue that these highly purified preparations—grown under high-nutrient conditions containing divalent cations—do not accurately represent the endotoxin likely to contaminate a parenteral product. Water from upstream purification systems is the most probable contamination source, and organisms in purified water systems adapt to low-cation environments via the PhoP/PhoQ system, stabilizing their outer membrane without relying on divalent cations.
: These agents bind to the divalent cations (like Mg2+cap M g raised to the 2 plus power Ca2+cap C a raised to the 2 plus power
Short CTA: Read PDA Technical Report 82 for practical patterns you can apply today to optimize edge devices and embedded controllers.
Low Endotoxin Recovery (LER), often referred to as endotoxin masking, has been a significant challenge in the pharmaceutical industry since its introduction to the industry by Cheng et al. in 2013. The phenomenon poses a critical risk to patient safety, as it involves the masking of environmental endotoxins in certain drug formulations, making them undetectable by standard Bacterial Endotoxin Testing (BET) methods.
In September 2023, the European Medicines Agency (EMA) published its , which specifically addresses when LER should be investigated. The answer was subsequently updated to refer directly to PDA TR 82 as a guidance document for these studies .